
Scope Fluidics is a biotechnology company developing microfluidic projects for medical diagnostics and healthcare.
scopefluidics.comCrawled Nov 9, 2026
Scope Fluidics SA develops microfluidic-based projects for medical diagnostics and health protection. The company’s group includes Curiosity Diagnostics and Bacteromic, which focus on the PCR ONE system for rapid disease diagnosis and the BacterOMIC diagnostic system, respectively.
Scope Fluidics is pursuing CE-IVDR certification for its **BACTEROMIC system**, a 6-hour diagnostic panel targeting **Gram-negative bacteria** with broad antibiotic coverage. The **UNI FAST Pro GN Panel** aims to streamline bacterial identification and resistance testing for clinical use. If certified, the panel could reach market availability in **2027**.
Edocera, a subsidiary of Scope Fluidics Group, completes a device prototype that detects early signs of stroke in in vivo lab tests. The achievement fulfills Objective II of its project, aligning with planned timelines. The technology targets stroke diagnosis through prototype validation.
Hybolic, a subsidiary of Scope Fluidics Group, secures up to **PLN 14.4 million** in funding from the Polish Agency for Enterprise Development (PARP) to advance its **HYBOLIC system**. The device measures **insulin and glucose concentrations** to enable personalized treatment of metabolic diseases. The project targets precision diagnostics for conditions like diabetes.
Scope Fluidics Group’s subsidiary **Bacteromic** receives a U.S. patent for its **AI-driven method and system** that predicts microorganism growth. The innovation builds on the company’s focus on AI applications in microbiology, expanding its intellectual property portfolio in diagnostic technology. The patent covers both the predictive algorithm and its integration into a functional system.
Scope Fluidics Group’s subsidiary, Bacteromic, partners with Biomedica Medizinprodukte GmbH to distribute the **BACTEROMIC system** across **10 European markets**. The agreement includes promotion, evaluation, and distribution, leveraging Biomedica’s presence in **13 countries**. The deal expands Bacteromic’s reach in diagnostics within Europe.
Scope Fluidics Group’s subsidiary, Bacteromic, partners with COMAC Medical to advance clinical trials of its **BACTEROMIC system PBC Panel**, a diagnostic tool for bacterial infection detection. The collaboration aims to validate the system’s performance in real-world medical settings. Scope Fluidics, listed on the Warsaw Stock Exchange, develops microfluidic-based diagnostic solutions.
Scope Fluidics Group’s subsidiary **Bacteromic** has secured a new facility to install and launch a **semi-automated production line** for its **BACTEROMIC system panels**. The move supports expanded manufacturing capacity for the company’s diagnostic panels, though no specific timeline or output details have been disclosed.
Scope Fluidics Group’s subsidiary **Bacteromic** secures **CE IVDR certification** for its **BACTEROMIC system with the UNI FAST Panel**, expanding its regulatory approvals in Europe. The certification follows an earlier IVDR approval for the system with the **UNI Panel** in February, enabling broader market access and commercial growth for the diagnostics solution.